title: Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
abstract: OBJECTIVE
  A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma.
  
  
  METHODS
  RECORD-3 used a crossover treatment design. The primary objective was to assess progression-free survival (PFS) noninferiority of first-line everolimus compared with first-line sunitinib. Secondary end points included combined PFS for each sequence, overall survival (OS), and safety.
  
  
  RESULTS
  Of 471 enrolled patients, 238 were randomly assigned to first-line everolimus followed by sunitinib, and 233 were randomly assigned to first-line sunitinib followed by everolimus. The primary end point was not met; the median PFS was 7.9 months for first-line everolimus and 10.7 months for first-line sunitinib (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.8). Among patients who discontinued first-line, 108 (45%) crossed over from everolimus to second-line sunitinib, and 99 (43%) crossed over from sunitinib to second-line everolimus. The median combined PFS was 21.1 months for sequential everolimus then sunitinib and was 25.8 months for sequential sunitinib then everolimus (HR, 1.3; 95% CI, 0.9 to 1.7). The median OS was 22.4 months for sequential everolimus and then sunitinib and 32.0 months for sequential sunitinib and then everolimus (HR, 1.2; 95% CI, 0.9 to 1.6). Common treatment-emergent adverse events during first-line everolimus or sunitinib were stomatitis (53% and 57%, respectively), fatigue (45% and 51%, respectively), and diarrhea (38% and 57%, respectively).
  
  
  CONCLUSIONS
  Everolimus did not demonstrate noninferiority compared with sunitinib as a first-line therapy. The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression.
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland. motzerr@mskcc.org.
authors: Robert J
authors: RJ
authors: Motzer
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Carlos H
authors: CH
authors: Barrios
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Tae Min
authors: TM
authors: Kim
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Silvia
authors: S
authors: Falcon
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Thomas
authors: T
authors: Cosgriff
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: W Graydon
authors: WG
authors: Harker
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Vichien
authors: V
authors: Srimuninnimit
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Ken
authors: K
authors: Pittman
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Roberto
authors: R
authors: Sabbatini
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Sun Young
authors: SY
authors: Rha
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Thomas W
authors: TW
authors: Flaig
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Ray
authors: R
authors: Page
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Sevil
authors: S
authors: Bavbek
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: J Thaddeus
authors: JT
authors: Beck
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Poulam
authors: P
authors: Patel
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Foon-Yiu
authors: FY
authors: Cheung
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Sunil
authors: S
authors: Yadav
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Edward M
authors: EM
authors: Schiff
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Xufang
authors: X
authors: Wang
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Julie
authors: J
authors: Niolat
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Dalila
authors: D
authors: Sellami
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Oezlem
authors: O
authors: Anak
authors: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.
authors: Jennifer J
authors: JJ
authors: Knox
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D018592:Cross-Over Studies; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D000068338:Everolimus; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077210:Sunitinib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus